LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Accueil・Liste d'Actions・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Fermé

SecteurSoins de santé

1.16 -0.85

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.1400000000000001

Max

1.17

Chiffres clés
By Trading Economics
Revenu	-16M -13M
Ventes	-15M 14M
BPA	-0.04
Marge bénéficiaire	-90.037
Employés	103
EBITDA	-16M -10M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+236.44% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-47M 447M
Ouverture précédente	2.01
Clôture précédente	1.16

Sentiment de l'Actualité

By Acuity

50%

165 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

0.6863 / 0.72 Support & Résistance

Lexicon Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 déc. 2025, 17:29 UTC

Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 déc. 2025, 16:47 UTC

Principaux Mouvements du Marché

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 déc. 2025, 16:10 UTC

Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19 déc. 2025, 22:33 UTC

Résultats

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 déc. 2025, 22:19 UTC

Résultats

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 déc. 2025, 21:48 UTC

Acquisitions, Fusions, Rachats

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 déc. 2025, 21:44 UTC

Résultats

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 déc. 2025, 21:38 UTC

Résultats

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 déc. 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 déc. 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19 déc. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 déc. 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 déc. 2025, 18:00 UTC

Market Talk

Résultats

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 déc. 2025, 17:41 UTC

Résultats

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 déc. 2025, 17:24 UTC

Market Talk

Résultats

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 déc. 2025, 17:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

19 déc. 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19 déc. 2025, 16:29 UTC

Résultats

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 déc. 2025, 16:20 UTC

Acquisitions, Fusions, Rachats

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 déc. 2025, 16:19 UTC

Acquisitions, Fusions, Rachats

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 déc. 2025, 16:18 UTC

Acquisitions, Fusions, Rachats

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 déc. 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 déc. 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 déc. 2025, 16:05 UTC

Acquisitions, Fusions, Rachats

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 déc. 2025, 16:04 UTC

Acquisitions, Fusions, Rachats

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 déc. 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19 déc. 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19 déc. 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19 déc. 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19 déc. 2025, 15:09 UTC

Résultats

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Comparaison

Variation de prix

Lexicon Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

236.44% hausse

Prévisions sur 12 Mois

Moyen 3.97 USD 236.44%

Haut 6 USD

Bas 1.9 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

Achat

Maintien

Vente

Basé sur 3 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

0.6863 / 0.72Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

165 / 374Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.